Longer lives, bigger profits: Why I’m bullish on GlaxoSmithKline plc, McCarthy and Stone plc and Carnival plc

Will adding GlaxoSmithKline (LON:GSK), McCarthy and Stone (LON:MCS) and Carnival (LON:CCL) give vitality to your portfolio?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Life expectancy has grown rapidly over recent decades. This is a good thing for us, of course, and it may also be good for our investments. Today, I’ll be looking at three companies that are likely to benefit most.

In need of a health kick?

People will always need medicine, especially as populations (particularly in developing markets) continue to grow and as developed world citizens live longer. With this in mind, adding a pharmaceutical giant to your portfolio may be a shrewd move.

GlaxoSmithKline (LSE:GSK) seems as good a candidate as any. Shares have disappointed over the last few years, dipping to 1,237p last September as a result of concerns surrounding the loss of profit-generating patents. Things now seem to be on the mend. The forthcoming departure of CEO Sir Andrew Witty and some positive figures in the April’s Q1 earnings release has led analysts to start re-evaluating the company and its future prospects.

Glaxo’s share currently trade at 1,410p. While not screamingly cheap with a P/E ratio of 16, the accompanying 80p per share dividend is a fairly decent sticking plaster for now. Although there have been concerns about Glaxo’s ability to cover this payout, these should abate if the company can prove it’s still on the road to recovery when it announces its Q2 results at the end of July.

Time to build a position?

Shares in retirement homes builder, McCarthy and Stone (LSE:MCS) have dropped rather heavily since their peak of 287p in January, perhaps more as a result of general market jitters and the forthcoming EU referendum than anything to do with the company itself. Indeed, the firm’s first set of half-year results since returning to the market last August certainly gave investors reason for cheer.

Reporting a 33% rise in revenue, Chairman John Wright commented that the group had made “strong progress” towards its goal of building and selling more than 3,000 properties every year. Underlying profit before tax increased by 23% to £39.1m with legal completions up by 19% to 923 units. A 1p interim dividend may sound miserly compared to huge payouts offered by other housebuilders, but this dividend is expected to rise rapidly to 6.78p in 2017, covered over three times by earnings.

Having a 70% share in this niche market gives McCarthy and Stone a dominant position over competitors, something that may become even more apparent as a greater proportion of baby boomers downsize. A 26% jump in the order book from £243m to £306m in one year would appear to back this up.

Calm waters ahead 

The imminent maiden voyage of the gigantic Harmony of the Seas cruise liner has made headlines this week. Cruises have appealed to those in retirement but the fact that people are now far more active in their senior years, and given that it’s the fastest growing sector of the global tourism industry, would suggest companies like Carnival (LSE:CCL) will benefit massively now and in the future.

According to Stockopedia, the £27bn cap has a PEG ratio of 0.89 for the current year. Experienced investors will know that anything under 1 signals they’re getting a lot of growth for their money. A dividend yield of just under 2.5%, while fairly average for a mature FTSE100 company, indicates the board is confident of profits being on a steady course.

Paul Summers owns shares in GlaxoSmithKline and McCarthy and Stone.  The Motley Fool has recommended shares in GlaxoSmithKline.  We fools don’t all hold the same views but we all believe that considering a diverse range of insights makes us better investors.

 

More on Investing Articles

Investing Articles

Up 50% in a year! Now check out the intriguing BP share price forecast for the next 12 months

The BP share price is up one day, down the next, as geopolitical uncertainty rattles the FTSE 100. Harvey Jones…

Read more »

Investing Articles

Is now the perfect time to buy high-yield FTSE 100 dividend shares? 

Harvey Jones says UK dividend shares have a brilliant track record of delivering income and growth, and he can see…

Read more »

Bronze bull and bear figurines
Investing Articles

At 7,000 points, the S&P 500 looks bloated. How should investors navigate this market?

AI-hype may have ballooned the S&P 500 into the mother of all bubbles – but only time will tell. For…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

How £100 can start a portfolio of UK stocks

Whether it’s building wealth or earning passive income, UK investors might be surprised at what £100 a month in stocks…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

How £16,000 can generate a second income in a Stocks and Shares ISA

Stephen Wright explains how UK investors can target an immediate £1,224 annual second income from UK dividend shares with a…

Read more »

Bronze bull and bear figurines
Investing Articles

This crazy growth stock is up 97% inside 2 months in my ISA!

Hims & Hers Health (NYSE:HIMS) is both an exciting and incredibly volatile growth stock. What on earth has sent it…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

How to target a million-pound SIPP by investing in UK shares

Harvey Jones shows how investors could target a SIPP worth a life-changing seven-figure sum, by investing in FTSE 100 dividend…

Read more »

A rear view of a female in a bright yellow coat walking along the historic street known as The Shambles in York, UK which is a popular tourist destination in this Yorkshire city.
Investing Articles

Buying £20k of BAE Systems shares could give me a £360 income this year!

Looking for the best dividend stocks out there? Royston Wild explains why BAE Systems shares are worth considering.

Read more »